Press Releases 2019
Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia
-
Thu, 03-Oct-2019
- Posted by: Biocon Biologics
No Comments
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs
-
Thu, 26-Sep-2019
- Posted by: Biocon Biologics
Biocon Biologics Expands its R&D Footprint Through Acquisition
-
Tue, 24-Sep-2019
- Posted by: Biocon Biologics
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
-
Thu, 22-Aug-2019
- Posted by: Biocon Biologics
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
-
Thu, 01-Aug-2019
- Posted by: Biocon Biologics
Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr
-
Thu, 25-Jul-2019
- Posted by: Biocon Biologics
Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers
-
Wed, 22-May-2019
- Posted by: Biocon Biologics
Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Thu, 16-May-2019
- Posted by: Biocon Biologics
Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr
-
Thu, 25-Apr-2019
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia
-
Wed, 13-Mar-2019
- Posted by: Biocon Biologics
